ORMP News and Press, Oramed Pharmaceuticals Inc. From 07/12/22

Gainers: Greenwich LifeSciences ( GLSI ) +41% . Histogen ( HSTO ) +37% . Oramed Pharmaceuticals ( ORMP ) +25% . InMode ( INMD ) +13% . Annexon ( ANNX ) +11% . Losers: Can-Fite BioPharma ( CANF ) -11% . Arc...

Oramed to Present at the Upcoming Canaccord Genuity Annual Growth Conference PR Newswire NEW YORK , July 11, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) ( www.oramed.com ), a clinical-stage pharmaceutical company focus...

Shares of the clinical-stage biotech Oramed Pharmaceuticals (NASDAQ: ORMP) were up by a staggering 41.6% as of 3:30 p.m. ET on Friday afternoon. What's more, this sizable move northwards is being accompanied by a huge uptick in volume, with more than 14.5 million shares traded at th...

Gainers: Seritage Growth Properties ( SRG ) +72% . Aditxt ( ADTX ) +70% . Humanigen ( HGEN ) +35% . Clovis Oncology ( CLVS ) +30% . MyMD Pharmaceuticals ( MYMD ) +27% . Oramed Pharmaceuticals ( ORMP ) +26% . Kura ...

Oramed Pharmaceuticals ( NASDAQ: ORMP ), a clinical-stage pharma focused on diabetes and liver diseases announced on Thursday that despite the challenges in enrollment, the company plans to share data from its Phase 1 trial for oral COVID-19 shot Oravax in 2Q 2022. Issuing...

Oramed Letter to Shareholders PR Newswire $169 Million in Cash and Investments Pivotal Phase 3 Oral Insulin Data Expected January 2023 Phase 2 NASH Data Expected This Quarter Oravax - Oral Vaccine NEW YORK , July 7,...

Oramed Appoints Dr. Anne Peters to its Scientific Advisory Board PR Newswire NEW YORK , June 1, 2022 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug d...

Oramed Pharma (NASDAQ:ORMP) said on Tuesday that the United States Patent and Trademark Office had granted a patent for methods and compositions for treating diabetes. The patent is for methods and compositions for treating diabetes mellitus through oral pharmaceutical compositions compr...

Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes Oramed Granted U.S. Combination Therapy Patent for Oral GLP-1 & Insulin for the Treatment of Diabetes PR Newswire NEW YORK , May 24, 2022 /PR...

Oramed Completes Patient Enrollment in Pivotal Phase 3 Oral Insulin Study ORA-D-013-1 PR Newswire ORMD-0801 positioned to potentially be the first FDA approved oral insulin for the treatment of diabetes Completed enrollment of 710 patients for the Phase...